ERBB2 and breast carcinoma: As RANK expression increased after dual lapatinib/trastuzumab treatment in HER2-positive breast cancer patients, we decided to test whether in vitro short-term treatment with both anti-HER2 drugs, alone or in combination, would influence RANK expression in three different HER2-positive breast cancer cell lines.